Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Registration Number
- NCT01515813
- Locations
- 🇺🇸
UCLA CARE Center CRS (601), Los Angeles, California, United States
🇺🇸Regional Center for Infectious Disease, Wendover Medical Center CRS (3203), Greensboro, North Carolina, United States
🇺🇸Houston AIDS Research Team CRS (31473), Houston, Texas, United States
The Neurocognitive Sub-study of Encore1
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 71
- Registration Number
- NCT01516060
- Locations
- 🇹🇭
HIVNAT Research Collaboration, Bangkok, Thailand
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Placebo matching with BMS-986001
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 297
- Registration Number
- NCT01489046
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Jacobi Medical Center, Bronx, New York, United States
🇹🇭Local Institution, Nontaburi, Thailand
A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- Mutual Pharmaceutical Company, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01472380
- Locations
- 🇺🇸
INC Research, Morgantown, West Virginia, United States
The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 32
- Registration Number
- NCT01451333
- Locations
- 🇹🇭
Khon Kaen University, Khon Kaen, Thailand
🇩🇪Medical Group Practice, Berlin, Germany
🇹🇭HIVNAT Research Collaboration, Patumwan, Bangkok, Thailand
A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)
- Conditions
- HIV
- Interventions
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- Göteborg University
- Target Recruit Count
- 242
- Registration Number
- NCT01445223
- Locations
- 🇸🇪
Department of Infectious Diseases, Goteborg, Sweden
Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
- Conditions
- HIV
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- University of Zimbabwe
- Target Recruit Count
- 19
- Registration Number
- NCT01410058
- Locations
- 🇿🇼
Parirenyatwa Hospital OI Clinic, Harare, Zimbabwe
Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression
- Conditions
- Antiretroviral Treatment Outcomes
- Interventions
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2017-04-20
- Target Recruit Count
- 59
- Registration Number
- NCT01387022
- Locations
- 🇿🇦
CAPRISA, Durban, KwaZulu-Natal, South Africa
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
- Conditions
- HIV Infection
- Interventions
- Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDCDrug: Rifampin/isoniazid FDC
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 851
- Registration Number
- NCT01380080
- Locations
- 🇮🇳
BJ Medical College CRS, Pune, Maharashtra, India
🇮🇳YRG CARE Medical Ctr., VHS Chennai CRS, Rajiv Gandhi Salai Taramani, Chennai, India
🇭🇹GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port Au Prince, Haiti
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
- Conditions
- HIV-1 InfectionKaposi's Sarcoma
- Interventions
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 192
- Registration Number
- NCT01352117
- Locations
- 🇰🇪
Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho, Kenya
🇺🇬JCRC CRS, Kampala, Uganda
🇲🇼University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.